Immunologic Reconstitution After Rituximab in Systemic Lupus Erythematosus: Why Should We Care?

Anolik, Jennifer H.

doi:10.3899/jrheum.101350

Cited by 2 publications

(1 citation statement)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CD20 is a member of a family of membrane proteins expressed on immature, naïve, memory, and germinal center B cells but not on pre-b or plasma cells [Anolik, 2011]. In vitro rituximab can kill B cells in a variety of ways.…”

Section: B-cell-targeted Therapiesmentioning

confidence: 99%

Novel treatments for systemic lupus erythematosus

Xiong

Lahita

2011

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

There are many new therapeutic directions for the disease systemic lupus erythematosus (SLE). Despite this, the US Food and Drug Administration (FDA) has approved only one biological agent and it involves B cells, now thought to play a significant role in the pathogenesis of SLE. The name of the drug is belimumab, which is an agent that removes the B-cell cytokine called B lymphocyte stimulation factor (BLyS). Rituximab did not achieve its primary endpoints, even though the consensus is that it may be effective in some forms of SLE including renal disease. The anticytokine therapies against interleukin (IL)-6, IL-10, IL-17 and tumor necrosis factor (TNF) are effective in their own ways and phase II and III trials are in progress.Of particular interest to immunologists are the anti-interferon alpha and gamma drugs, which show promise in the animal models. Modulation of costimulatory molecules; specifically, the anti CD40, CTLA-Ig and ICOS/B7RP blockade agents offer possibilities for the future using new pathways heretofore limited to rheumatoid arthritis. Finally, the use of tyrosine kinase inhibitors is another direction that has been successful in the inhibition of SLE in the murine model; early trials in human SLE have begun.

show abstract

Section: B-cell-targeted Therapiesmentioning

confidence: 99%